New research has revealed that structurally novel neurokinin-1 receptor (NK1R) inhibitors reduce depressive-like behaviour and brain inflammation in mice. 

For decades, scientists have investigated the NK1R as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs such as aprepitant failed to show clear benefits. 

In a new study led by Professors Hyeijung Yoo, Hong-Rae Kim, and Hyun Kim from Korea University, the team shows that redesigning the molecular structure of NK1R antagonists can restore antidepressant-like effects in preclinical models.  

By removing a chemical group commonly found in earlier drug candidates and replacing it with a structurally distinct scaffold, the researchers identified new compounds that reduced depressive-like behaviour and neuroinflammation in mice.  

Professor Hong-Rae said: “Our findings suggest that the structurally distinct antagonists identified in this study exhibit antidepressant-like effects, providing renewed evidence for further exploration of NK1R antagonism as a therapeutic strategy for MDD.” 

Using machine-learning-based virtual screening, the team analysed millions of molecules to identify NK1R antagonists lacking the commonly used 3,5-bis-trifluoromethylphenyl (TFMP) group, which may contribute to inconsistent clinical outcomes. Several candidates were tested, with compound number15 showing strong activity. In mouse models of stress- and inflammation-induced depression, it reduced depressive-like behaviours and neuroinflammation without affecting locomotion, while binding the NK1 receptor through a distinct interaction profile. 

The authors say the study has implications beyond depression. Because inflammation is increasingly recognised as a contributor to poor antidepressant response in some patients, structurally novel NK1R antagonists could eventually be explored for inflammation-linked depression subtypes.  

Professor Hong-Rae concluded: “Our results provide a foundation for optimising NK1R antagonists and underscore the importance of structural diversity, which could lead to new therapeutic options in treatment-resistant or inflammation-associated depression.”

Diana Turner, Deputy Editor, DDW